Aventis and Watson Reach Settlement on Litigation

01-Oct-2001

Aventis Pharma AG, the pharmaceutical company of Aventis, announced today that it has settled litigation with Watson Pharmaceuticals Inc. related to the hypertension drug Dilacor® XR (dilatizem).

Terms of the settlement were not material to the financial position of Aventis, which previously had recorded reserves for potential liability in connection with the dispute.

The settlement relates to a lawsuit filed by Watson in a U.S. District Court in California in August 1999 against Rhone Poulenc Rorer Inc., a predecessor company of Aventis. The lawsuit alleged breach of a manufacturing and supply agreement and a non-compete clause contained in a 1997 license agreement granting certain rights to Dilacor XR® to Watson.

Other news from the department science

More news from our other portals

So close that even
molecules turn red...